Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Institutional update .
View:
Post by jh1970 on Oct 06, 2024 9:13pm

Institutional update .

"ONCY on 8/14 Institutional Shares were 1,597,477 - 2.08% and today (10/5) Institutional Shares are now 73,834,059 - 58.38%"
From other investor web. Very interesting info.
Comment by spesestsemper on Oct 06, 2024 9:21pm
Don't think this is anywhere near accurate . Someone posting it doesnt make it true . They provide no link to a source and the numbers don't even make sense 
Comment by spesestsemper on Oct 06, 2024 9:25pm
ONCY - Oncolytics Biotech Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM) (fintel.io) thats up to oct 4th
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities